Capstone Investment Advisors LLC Takes Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Capstone Investment Advisors LLC acquired a new position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 13,089 shares of the biopharmaceutical company’s stock, valued at approximately $727,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. nVerses Capital LLC bought a new position in shares of Ultragenyx Pharmaceutical in the second quarter worth $33,000. UMB Bank n.a. lifted its holdings in Ultragenyx Pharmaceutical by 58.1% in the second quarter. UMB Bank n.a. now owns 958 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 352 shares during the period. Values First Advisors Inc. bought a new position in Ultragenyx Pharmaceutical in the 3rd quarter valued at about $56,000. Capital Performance Advisors LLP acquired a new position in Ultragenyx Pharmaceutical during the 3rd quarter valued at about $107,000. Finally, Quest Partners LLC bought a new stake in shares of Ultragenyx Pharmaceutical during the 3rd quarter worth about $119,000. 97.67% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on RARE shares. JPMorgan Chase & Co. decreased their price objective on shares of Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an “overweight” rating for the company in a report on Thursday, November 21st. Wells Fargo & Company lifted their price target on Ultragenyx Pharmaceutical from $72.00 to $75.00 and gave the company an “overweight” rating in a research report on Friday, August 2nd. Wedbush boosted their price objective on Ultragenyx Pharmaceutical from $43.00 to $46.00 and gave the stock a “neutral” rating in a research note on Friday, August 2nd. TD Cowen raised their target price on Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the company a “buy” rating in a research note on Monday, October 21st. Finally, HC Wainwright boosted their price target on shares of Ultragenyx Pharmaceutical from $82.00 to $95.00 and gave the stock a “buy” rating in a research report on Wednesday, November 6th. Two investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $87.46.

Insider Activity

In related news, CEO Emil D. Kakkis sold 20,000 shares of Ultragenyx Pharmaceutical stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $55.85, for a total transaction of $1,117,000.00. Following the completion of the sale, the chief executive officer now owns 2,223,985 shares of the company’s stock, valued at approximately $124,209,562.25. This trade represents a 0.89 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Howard Horn sold 7,465 shares of the firm’s stock in a transaction dated Thursday, October 10th. The stock was sold at an average price of $52.76, for a total value of $393,853.40. Following the sale, the chief financial officer now directly owns 92,301 shares of the company’s stock, valued at $4,869,800.76. This trade represents a 7.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 27,556 shares of company stock worth $1,515,967 in the last 90 days. Company insiders own 5.80% of the company’s stock.

Ultragenyx Pharmaceutical Stock Performance

NASDAQ RARE opened at $48.13 on Friday. The firm’s 50 day moving average price is $52.26 and its two-hundred day moving average price is $48.57. The stock has a market cap of $4.44 billion, a price-to-earnings ratio of -7.44 and a beta of 0.58. Ultragenyx Pharmaceutical Inc. has a twelve month low of $37.02 and a twelve month high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) earnings per share for the quarter, beating the consensus estimate of ($1.45) by $0.05. Ultragenyx Pharmaceutical had a negative return on equity of 187.12% and a negative net margin of 106.93%. The firm had revenue of $139.49 million for the quarter, compared to analyst estimates of $135.28 million. During the same period in the previous year, the firm earned ($2.23) earnings per share. Ultragenyx Pharmaceutical’s quarterly revenue was up 42.3% on a year-over-year basis. On average, research analysts forecast that Ultragenyx Pharmaceutical Inc. will post -6.2 EPS for the current fiscal year.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.